MARIA TAPIA: Open Payments
NPI 1962874214 · NEW BRITAIN, CT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,030 in 87 payments from 11 companies in 2025. Trend: 2023 $1,820 · 2024 $2,145 · 2025 $2,030
Food & beverage: $1,906Education: $123
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 14 | $525 |
| ABBVIE INC. | 39 | $502 |
| Vanda Pharmaceuticals Inc. | 5 | $229 |
| Supernus Pharmaceuticals, Inc. | 6 | $180 |
| Otsuka America Pharmaceutical, Inc. | 13 | $172 |
| Axsome Therapeutics, Inc. | 2 | $143 |
| Janssen Pharmaceuticals, Inc | 1 | $125 |
| Indivior Inc. | 4 | $89 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $24 |
| E.R. Squibb & Sons, L.L.C. | 1 | $21 |
Products named: VRAYLAR, AUSTEDO XR, FANAPT, Qelbree, Auvelity, UZEDY, INVEGA SUSTENNA, ABILIFY ASIMTUFII.
Industry payments across CT — which companies pay providers there.
